vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v20i6S.2372vsp-2782Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEАллергические реакции при ферментозаместительной терапии детей с мукополисахаридозом, тип IIAllergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type IIhttps://orcid.org/0000-0002-2460-7718ЛевинаЮ. Г.LevinaJulia G.

Левина Юлия Григорьевна, кандидат медицинских наук, заведующая отделом клинической иммунологии и аллергологии, врач аллерголог-иммунолог НИИ педиатрии и охраны здоровья детей ЦКБ РАН

119333, Москва, ул. Фотиевой, д. 10 стр. 1

Moscow

julia.levina@mail.ruhttps://orcid.org/0000-0001-8320-2027ВашакмадзеН. Д.VashakmadzeNato D.

Москва

Moscow

https://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Москва; Белгород

Moscow; Belgorod

https://orcid.org/0000-0001-7398-0562ВишневаЕ. А.VishnevaElena A.

Москва

Moscow

https://orcid.org/0000-0001-6614-6115ЖурковаН. В.ZhurkovaNatalia V.

Москва

Moscow

https://orcid.org/0000-0003-0317-2425ЭфендиеваК. Е.EfendievaKamilla E.

Москва

Moscow

https://orcid.org/0000-0001-5665-7835АлексееваА. А.AlekseevaAnna A.

Москва

Moscow

https://orcid.org/0000-0002-3781-8661КалугинаВ. Г.KaluginaVera G.

Москва

Moscow

Научно-исследовательский институт педиатрии и охраны здоровья детей Центральной клинической больницы Российской академии наук; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical UniversityRussian FederationНаучно-исследовательский институт педиатрии и охраны здоровья детей Центральной клинической больницы Российской академии наук; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова; Белгородский государственный национальный исследовательский университетРоссияResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University; Belgorod State National Research UniversityRussian FederationНаучно-исследовательский институт педиатрии и охраны здоровья детей Центральной клинической больницы Российской академии наук; Медико-генетический научный центр им. академика Н.П. БочковаРоссияResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Medical Genetic Research Center named after N.P. BochkovRussian FederationНаучно-исследовательский институт педиатрии и охраны здоровья детей Центральной клинической больницы Российской академии наукРоссияResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”Russian Federation202117122021206s624629Copyright © Левина Ю.Г., Вашакмадзе Н.Д., Намазова-Баранова Л.С., Вишнева Е.А., Журкова Н.В., Эфендиева К.Е., Алексеева А.А., Калугина В.Г., 20212021Левина Ю.Г., Вашакмадзе Н.Д., Намазова-Баранова Л.С., Вишнева Е.А., Журкова Н.В., Эфендиева К.Е., Алексеева А.А., Калугина В.Г.Levina J.G., Vashakmadze N.D., Namazova-Baranova L.S., Vishneva E.A., Zhurkova N.V., Efendieva K.E., Alekseeva A.A., Kalugina V.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2782

Мукополисахаридоз, тип II (МПС II; синдром Хантера) — редкое наследственное заболевание, вызванное изменениями в структуре гена IDS и связанным с ними дефицитом лизосомного фермента идуронат-2-сульфатазы (I2S). Основой лечения детей с МПС II является ферментозаместительная терапия (ФЗТ) с рекомбинантной человеческой I2S. Одной из основных проблем ФЗТ является развитие аллергических, в том числе тяжелых анафилактических, реакций на рекомбинантные ферменты. В статье рассмотрены особенности инфузионных реакций гиперчувствительности при ФЗТ, описаны патогенез, диагностические критерии и алгоритм лечения анафилаксии. Обоснована необходимость дальнейших исследований аллергических инфузионных реакций у детей при ФЗТ.

Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is rare hereditary disease caused by changes in the IDS gene and associated deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The main treatment scheme for children with MPS II is enzyme replacement therapy (ERT) with recombinant human I2S. The major issue of ERT is development of allergic (sometimes up to severe anaphylaxis) reactions to recombinant enzymes. The article covers features of infusion-related reactions to ERT, it describes pathogenesis, diagnostic criteria management algorithm of anaphylaxis. Whereas, there is the need of further studies on allergic infusion-related reactions to ERT in children.

мукополисахаридозтип IIферментозаместительная терапияидурсульфазаидурсульфаза бетаинфузионные реакциианафилаксияmucopolysaccharidosis type IIenzyme replacement therapyidursulfaseidursulfase betainfusion-related reactionsanaphylaxisReferencesSestito S, Ceravolo F, Grisolia M, et al. Profile of idursulfase for the treatment of Hunter syndrome. Research and Reports in Endocrine Disorders. 2015;5:79–90. doi: 10.2147/RRED.S64347Sestito S, Ceravolo F, Grisolia M, et al. Profile of idursulfase for the treatment of Hunter syndrome. Research and Reports in Endocrine Disorders. 2015;5:79–90. doi: 10.2147/RRED.S64347Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465–473. doi: 10.1097/01.gim.0000232477.37660.fbMuenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465–473. doi: 10.1097/01.gim.0000232477.37660.fbSohn YB, Cho SY, Park SW, et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis. 2013;8:42. doi: 10.1186/1750-1172-8-42Sohn YB, Cho SY, Park SW, et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis. 2013;8:42. doi: 10.1186/1750-1172-8-42Мукополисахаридоз тип II: клинические рекомендации / Союз педиатров России; Ассоциация медицинских генетиков. — МЗ РФ; 2021. — 79 с. Доступно по: https://cr.minzdrav.gov.ru/recomend/392_2. Ссылка активна на 11.12.2021.Mukopolisakharidoz tip II: Clinical guidelines. Union of Pediatricians of Russia; Association of Medical Geneticists. Ministry of Health of the Russian Federation; 2021. 79 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/recomend/392_2. Ссылка активна на 11.12.2021.Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2): 167–174. doi: 10.1038/jhg.2016.133Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2): 167–174. doi: 10.1038/jhg.2016.133Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther. 2009; 47 Suppl 1:S100–S106. doi: 10.5414/cpp47100Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther. 2009; 47 Suppl 1:S100–S106. doi: 10.5414/cpp47100Burton BK, Whiteman DA. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011;103(2):113–120. doi: 10.1016/j.ymgme.2011.02.018Burton BK, Whiteman DA. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011;103(2):113–120. doi: 10.1016/j.ymgme.2011.02.018Brooks DA, Kakavanos R, Hopwood JJ. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med. 2003;9(10):450–453. doi: 10.1016/j.molmed.2003.08.004Brooks DA, Kakavanos R, Hopwood JJ. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med. 2003;9(10):450–453. doi: 10.1016/j.molmed.2003.08.004Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420–437. doi: 10.1111/all.12350Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420–437. doi: 10.1111/all.12350Rasheed S, Nelson-Rees WA, Toth EM, et al. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer. 1974;33(4):1027–1033. doi: 10.1002/1097-0142(197404)33:4<1027::aid-cncr2820330419>3.0.co;2-zRasheed S, Nelson-Rees WA, Toth EM, et al. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer. 1974;33(4):1027–1033. doi: 10.1002/1097-0142(197404)33:4<1027::aid-cncr2820330419>3.0.co;2-zLai T, Yang Y, Ng SK. Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel). 2013;6(5):579–603. doi: 10.3390/ph60505799Lai T, Yang Y, Ng SK. Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel). 2013;6(5):579–603. doi: 10.3390/ph60505799Vojta A, Samaržija I, Bočkor L, Zoldoš V. Glyco-genes change expression in cancer through aberrant methylation. Biochim Biophys Acta. 2016;1860(8):1776–1785. doi: 10.1016/j.bbagen.2016.01.002Vojta A, Samaržija I, Bočkor L, Zoldoš V. Glyco-genes change expression in cancer through aberrant methylation. Biochim Biophys Acta. 2016;1860(8):1776–1785. doi: 10.1016/j.bbagen.2016.01.002D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. Int J Mol Sci. 2020;21(4):1258. doi: 10.3390/ijms21041258D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. Int J Mol Sci. 2020;21(4):1258. doi: 10.3390/ijms21041258Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj J. 2014;31(4):309–315. doi: 10.1007/s10719-014-9523-0Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj J. 2014;31(4):309–315. doi: 10.1007/s10719-014-9523-0Ngu LH, Ong Peitee W, Leong HY, Chew HB. Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II. Mol Genet Metab Rep. 2017;12: 28–32. doi: 10.1016/j.ymgmr.2017.05.002Ngu LH, Ong Peitee W, Leong HY, Chew HB. Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II. Mol Genet Metab Rep. 2017;12: 28–32. doi: 10.1016/j.ymgmr.2017.05.002Kim J, Park MR, Kim DS, et al. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome. Allergy. 2013;68(6):796–802. doi: 10.1111/all.12155Kim J, Park MR, Kim DS, et al. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome. Allergy. 2013;68(6):796–802. doi: 10.1111/all.12155Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccha ridosis II, MPS II). Mol Genet Metab. 2010;99(1):18–25. doi: 10.1016/j.ymgme.2009.08.006Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccha ridosis II, MPS II). Mol Genet Metab. 2010;99(1):18–25. doi: 10.1016/j.ymgme.2009.08.006Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007;7(5):365–378. doi: 10.1038/nri2072Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007;7(5):365–378. doi: 10.1038/nri2072Oettgen HC. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J Allergy Clin Immunol. 2016;137(6):1631–1645. doi: 10.1016/j.jaci.2016.04.009Oettgen HC. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J Allergy Clin Immunol. 2016;137(6):1631–1645. doi: 10.1016/j.jaci.2016.04.009Hamilton RG, MacGlashan DW Jr, Saini SS. IgE antibodyspecific activity in human allergic disease. Immunol Res. 2010; 47(1–3):273–284. doi: 10.1007/s12026-009-8160-3Hamilton RG, MacGlashan DW Jr, Saini SS. IgE antibodyspecific activity in human allergic disease. Immunol Res. 2010; 47(1–3):273–284. doi: 10.1007/s12026-009-8160-3Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(1 Suppl):S2–S24. doi: 10.1016/j.jaci.2007.05.001Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(1 Suppl):S2–S24. doi: 10.1016/j.jaci.2007.05.001Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S116–S125. doi: 10.1016/j.jaci.2009.08.028Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S116–S125. doi: 10.1016/j.jaci.2009.08.028Khodoun M, Strait R, Orekov T, et al. Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol. 2009;123(2):342–351. doi: 10.1016/j.jaci.2008.11.004Khodoun M, Strait R, Orekov T, et al. Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol. 2009;123(2):342–351. doi: 10.1016/j.jaci.2008.11.004Khodoun MV, Strait R, Armstrong L, et al. Identification of markers that distinguish IgE-from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A. 2011;108(30):12413–12418. doi: 10.1073/pnas.1105695108Khodoun MV, Strait R, Armstrong L, et al. Identification of markers that distinguish IgE-from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A. 2011;108(30):12413–12418. doi: 10.1073/pnas.1105695108Arias K, Chu DK, Flader K, et al. Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice. J Allergy Clin Immunol. 2011;127(6):1552–1561. e1. doi: 10.1016/j.jaci.2011.03.044Arias K, Chu DK, Flader K, et al. Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice. J Allergy Clin Immunol. 2011;127(6):1552–1561. e1. doi: 10.1016/j.jaci.2011.03.044de Silva D, Singh C, Muraro A, et al. Diagnosing, managing and preventing anaphylaxis: Systematic review. Allergy. 2021; 76(5):1493–1506. doi: 10.1111/all.14580de Silva D, Singh C, Muraro A, et al. Diagnosing, managing and preventing anaphylaxis: Systematic review. Allergy. 2021; 76(5):1493–1506. doi: 10.1111/all.14580Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472. doi: 10.1016/j.waojou.2020.100472Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472. doi: 10.1016/j.waojou.2020.100472Ильина Н.И., Заболотских И.Б., Астафьева Н.Г. и др. Анафилактический шок. Клинические рекомендации Российской ассоциации аллергологов и клинических иммунологов и Общероссийской общественной организации «Федерация анестезиологов и реаниматологов» // Вестник интенсивной терапии им. А.И. Салтанова. — 2020. — № 3. — С. 15–26. doi: 10.21320/1818-474X-2020-3-15-26Ilyina NI, Zabolotskikh IB, Astafieva NG, et al. Anaphylactic shock. Clinical guidelines of Russian Association of Allergists and Clinical Immunologists and the All-Russian Public Organization “Federation of Anesthesiologists and Reanimatologists”. Annals of Critical Care. 2020;(3):15–26. (In Russ). doi: 10.21320/1818-474X-2020-3-15-26Аллергология и иммунология / под ред. Л.С. Намазовой-Барановой, А.А. Баранова, Р.М. Хаитова. — М.: Союз педиатров России; 2020.Allergologiya i immunologiya. Namazova-Baranova LS, Baranov AA, Khaitov RM, eds. Moscow: Union of Pediatricians of Russia; 2020. (In Russ).Lieberman P, Nicklas R, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 Update. J Allergy Clin Immunol. 2010;126(3):477–480.e42. doi: 10.1016/j.jaci.2010.06.022Lieberman P, Nicklas R, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 Update. J Allergy Clin Immunol. 2010;126(3):477–480.e42. doi: 10.1016/j.jaci.2010.06.022Sala-Cunill V. Cardona Biomarkers of anaphylaxis, beyond tryptase. Curr Opin Allergy Clin Immunol. 2015;15(4):329–336. doi: 10.1097/ACI.0000000000000184Sala-Cunill V. Cardona Biomarkers of anaphylaxis, beyond tryptase. Curr Opin Allergy Clin Immunol. 2015;15(4):329–336. doi: 10.1097/ACI.0000000000000184Serrano CD, Gomez JF. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome). J Investig Allergol Clin Immunol. 2011;21(7):571–572.Serrano CD, Gomez JF. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome). J Investig Allergol Clin Immunol. 2011;21(7):571–572.Кручина Т.К., Бручиков К.В., Новик Г.А. Опыт применения препарата идурсульфаза бета у ребенка с мукополисахаридозом II типа: клинический случай // Вопросы современной педиатрии. — 2020. — Т. 19. — № 5. — С. 364–370. doi: 10.15690/vsp.v19i5.2212Kruchina TK, Bruchikov KV, Novik GA. Experience of Idursulfase Beta Administration in the Child with Mucopolysaccharidosis Type II: Clinical Case. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(5):364–370. (In Russ). doi: 10.15690/vsp.v19i5.2212Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140(2):335–348. doi: 10.1016/j.jaci.2017.06.003Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140(2):335–348. doi: 10.1016/j.jaci.2017.06.003Matheu V, Franco A, Pérez E, et al. Omalizumab for drug allergy. J Allergy Clin Immunol. 2007;120(6):1471–1472; author reply 1472–1473. doi: 10.1016/j.jaci.2007.07.03Matheu V, Franco A, Pérez E, et al. Omalizumab for drug allergy. J Allergy Clin Immunol. 2007;120(6):1471–1472; author reply 1472–1473. doi: 10.1016/j.jaci.2007.07.03Mishra S, Connors L, Tugwell B. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature. Diabet Med. 2018;35(5):663–666. doi: 10.1111/dme.13591Mishra S, Connors L, Tugwell B. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature. Diabet Med. 2018;35(5):663–666. doi: 10.1111/dme.13591Cavelti-Weder C, Muggli B, Keller C, et al. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care. 2012;(6):e41. doi: 10.2337/dc12-0115Cavelti-Weder C, Muggli B, Keller C, et al. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care. 2012;(6):e41. doi: 10.2337/dc12-0115Arroabarren E, Aznal E, Anda M, Sánchez-Valverde F. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadyuvant for enzyme replacement therapy desensitization. Pediatr Allergy Immunol. 2019;30(4):491–494. doi: 10.1111/pai.13049Arroabarren E, Aznal E, Anda M, Sánchez-Valverde F. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadyuvant for enzyme replacement therapy desensitization. Pediatr Allergy Immunol. 2019;30(4):491–494. doi: 10.1111/pai.13049

The authors declare that there are no conflicts of interest present.